Influvac Tetra 2025 Vaccine is a quadrivalent inactivated influenza vaccine designed for active immunization against influenza caused by influenza virus types A and B. The vaccine contains purified, inactivated viral antigens derived from four influenza virus strains, selected annually based on WHO recommendations to provide broad protection against circulating influenza viruses. Influvac Tetra 2025 is indicated for individuals aged six months and older to reduce the risk of influenza infection and its associated complications. The vaccine stimulates the immune system to produce protective antibodies against the hemagglutinin and neuraminidase surface proteins of the included virus strains. Administration is via intramuscular injection, typically as a single dose prior to the onset of the influenza season; a second dose may be recommended for certain pediatric populations. Common adverse reactions include injection site pain, tenderness, erythema, and mild systemic symptoms such as headache, myalgia, and low-grade fever, which are generally transient. Influvac Tetra 2025 is contraindicated in individuals with a history of severe allergic reactions to any component of the vaccine or previous dose. Immunization with Influvac Tetra 2025 does not confer immediate protection; therefore, continued adherence to preventive measures is advised during the influenza season.